Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

irinotecan (Rx)Brand and Other Names:Camptosar

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 20mg/mL
more...

Colorectal Cancer

Indicated as first-line therapy (with 5-fluorouracil and leucovorin) for metastatic colorectal cancer (CRC); it is also indicated for CRC that has recurred or progressed following intial fluorouracil-based therapy

Monotherapy

  • Patients should be premedicated with antiemetic agents
  • Atropine treatment should be considered in patients that experience cholinergic symptoms
  • Regimen 1 (Weekly): 125 mg/m² IV infusion over 90 minutes on days 1, 8, 15, 22, then 2 weeks off, then repeat 
  • Regimen 2 (Once Every 3 Weeks): 350 mg/sq.meter IV infusion over 30-90 minutes q3Weeks
  • Adjust dose per protocol

Combination therapy

  • Patients should be premedicated with antiemetic agents
  • Atropine treatment should be considered in patients that experience cholinergic symptoms
  • Regimen 1 (6 week cycle with infusional 5-fluorouracil/ leucovorin): 180 mg/m² IV infusion over 30-90 minutes once on days 1, 15, and 29 IV (infuse over 30-90 min), followed by infusion with leucovorin and 5-fluorouracil; next cycle begins on day 43 
  • Regimen 2 (6 week cycle with bolus 5-fluorouracil/ leucovorin): 125 mg/sq.meter on days 1, 8, 15, and 22 (infuse over 90 min), followed by bolus doses of leucovorin and 5-fluorouracil
  • Adjust dose per protocol

Pancreatic Cancer (Orphan)

Stable nanotherapeutic encapsulated irinotecan (MM-398; pegirinotecan)

Orphan indication sponsor

  • Merrimack Pharmaceuticals, Inc., 1 Kendall Square; Cambridge, MA 02139-1670

Ovarian Cancer (Orphan)

Peg-irinotecan: Treatment of ovarian cancer

Orphan indication sponsor

  • Nektar Theraeputics; 455 Mission Bay Blvd; South San Francisco, CA 94158

Other Indications & Uses

Off-label: advanced ovarian cancer, glioblastoma multiforme, NSCLC

Not recommended

Next

Interactions

Interaction Checker

irinotecan and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            >10%

            Anemia (>90%)

            Leukopenia (>90%)

            Neutropenia (>90%)

            Thrombocytopenia (>90%)

            Elevated bilirubin (88%)

            Diarrhea (85%)

            Nausea (79%)

            Asthenia (70%)

            Abdominal pain (63%)

            Vomiting (60%)

            Alopecia (43%)

            Fever (42%)

            Constipation (41%)

            Anorexia (34%)

            Mucositis (32%)

            Pain (31%)

            Dyspnea (28%)

            Cough (27%)

            Dizziness (23%)

            Infection (22%)

            Rash (19%)

            1-10%

            Abdominal fullness (10%)

            AST increased (10%)

            Dyspepsia (10%),

            Edema (10%)

            Ascites/jaundice (9%)

            Vasodilation (9%)

            Thromboembolism (9%)

            Hypotension (6%)

            Neutropenic fever (2-6%)

            Frequency Not Defined

            Headache

            Insomnia

            Orthostatic hypotension

            Previous
            Next

            Warnings

            Black Box Warnings

            The drug should be administered under the supervision of an experienced cancer chemotherapy physician in facility with appropriate personnel and equipment to diagnose and manage the complications resulting from the therapy.

            Early & late forms of severe diarrhea that may be mediated by different mechanisms have been reported. Following the irinotecan infusion, atropine can be used to treat or ameliorate the early diarrhea (occurring shortly after the infusion), which may be accompanied by cholinergic symptoms, including intestinal hyperperistalsis. Late diarrhea (after 24 hr of irinotecan infusion) can be life threatening because it can lead to dehydration, electrolyte imbalance, or sepsis. It should be treated promptly with loperamide, and patients should be given fluid and electrolytes if they become dehydrated or antibiotics if they develop fever.

            Severe myelosuppression may occur

            Contraindications

            Hypersensitivity

            Pregnancy

            Hereditary fructose intolerance (d/t sorbitol)

            Cautions

            Hyperbilirubinemia, elderly, receiving radiation therapy, abdominal/pelvic radiation history

            Not for use in combination with a regimen of 5-FU/LV administered for 4-5 consecutive days every 4 weeks outside of a clinical study

            Interstitial pulmonary disease (IPD)-like events, including fatalities, have been reported (in combination and as monotherapy) for treatment of colorectal cancer and other advanced solid tumors

            Diarrhea

            • Risk of both early and late forms of diarrhea (by different mechanisms)
            • Early form may be treated with atropine (0.25 mg to 1 mg of intravenous or subcutaneous atropine; unless clinically contraindicated)
            • Late form should be promptly treated with loperamide; also give fluid and electrolytes if necessary

            Risk of severe myelosuppression; manage febrile neutropenia promptly with antibiotic support; interrupt therapy and reduce subsequent doses if necessary

            Drug is subject to photodegradation, especially in neutral & alkaline solutions

            Individuals who are homozygous for the UGT1A1*28 allele are at increased risk for neutropenia following initiation of therapy; consider dose reduction by at least 1 level for pts homozygous in the enzyme UDP-glucuronosyl transferase 1A1*28 (UGT1A1*28) variant

            Avoid pregnancy

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: D

            Lactation: not known if excreted in breast milk, do not nurse

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Mechanism of Action

            Binds to topoisomerase I to produce double-strand breaks in DNA

            Pharmacokinetics

            Half-Life: 6-12 hr; SN-38 10-20 hr

            Pleak Plasma Concentration: 1660 ng/mL; SN-38 26.3 ng/mL

            Protein Bound: 30-68%; SN-38 95%

            Vd: 110-234 L/m²

            Metabolism: hepatic, to SN-38; SN-38 is further metabolized by UGT1A1

            Metabolites: SN-38

            Clearance: 13-14 L/hr/m²

            Excretion: urine, feces

            Pharmacogenomics

            Converted to SN-38 active metabolite; SN-38 is subsequently conjugated predominantly by the enzyme UDP-glucuronosyl transferase 1A1 (UGT1A1) to form a glucuronide metabolite

            UGT1A1 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity such as the UGT1A1*28 polymorphism

            Reduced UGT1A1 activity increases risk for neutropenia

            ~10% of North American population is homozygous for UGT1A1*28 variant; consider dose reduction in these patients

            Genetic testing laboratories

            • Genotyping tests are available through the following companies
            • ARUP Laboratories (http://www.aruplab.com/)
            • LabCorp (http://www.labcorp.com/)
            • Genzyme Genetics (http://www.genzymegenetics.com/)
            Previous
            Next

            Administration

            IV Incompatibilities

            Additive: methylprednisolone sodium succinate (10% loss in 3 hr)

            Y-site: gemcitabine

            IV Preparation

            Dilute in D5W to a final concentration of 0.12-2.8 mg/mL (most commonly in 500 mL D5W)

            NS can be used, but precipitation under refrigeration is more likely with NS, so D5W is generally preferred

            IV Administration

            Irritant

            Infuse over 90 min

            If administered in combination with fluorouracil & leucovorin, administer leucovorin immediately after irinotecan, & administer fluorouracil immediately after leucovorin

            Premedication with antiemetics (dexamethasone plus ondansetron/granisetron) is recommended, at least 30 min prior to infusion

            Atropine should be considered in pts experiencing cholinergic symptoms

            Storage

            Store at controlled room temp

            Protect from light

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.